Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Enter your email address below and subscribe to our newsletter
Access to hospital-based eye care and reimbursement were policy topics at the…
Phase 2 data for kamuvudine K8, an investigational inflammasome-directed treatment from Inflammasome…
Two transactions announced in September and October 2026 show capital moving through…
GenSight Biologics and the Quinze-Vingts National Ophthalmology Hospital in Paris announced on…
(Image Credit: Adobe Stock/fotofabrika) Ollin Biosciences has announced positive topline results from…
(Image Credit: AdobeStock/neosiam) A press release from the University of Washington, Seattle,…
With January being Glaucoma Awareness Month, it seems fitting to discuss neovascular…
Outlook Therapeutics, Inc. reported that the FDA has issued a complete response…
(Image Credit: AdobeStock) One of the most striking results with the Light…
In a year-end conversation, Oluwatosin U. Smith, MD, of Glaucoma Associates of…
Incorporating data from low- and middle-income countries may help redefine how ophthalmology…
In this segment, the panel compares the pivotal QUASAR trial of aflibercept…
This segment explores emerging data on aflibercept 8 mg for retinal vein…
Enter your email address below and subscribe to our newsletter